Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide and Tirzepatide in Delaying Genetic Aging in Adult Obese Patients
NCT07293325Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jun 2025
- Primary completion
- Apr 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of semaglutide and tirzepatide in obesity (3 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Change in DNA methylation-based biological age measured by iWatchAge at 24 weeks. Started Jun 2025; status: recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07293325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07293325.